Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report released on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Down 0.6 %

NASDAQ BCLI opened at $1.58 on Tuesday. The stock has a market cap of $9.01 million, a P/E ratio of -0.33 and a beta of 0.74. The company’s 50-day simple moving average is $1.83 and its 200 day simple moving average is $2.18. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.